Intersect ENT (XENT-1.2%) announces the enrollment of the first patient in its clinical study of NOVA, its investigational bioabsorbable steroid-releasing sinus implant. NOVA is designed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback